We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Biomarker Challenge to 'Revolutionize' Dementia Diagnosis

By LabMedica International staff writers
Posted on 26 Dec 2024

With approximately a third of the UK population living with undiagnosed dementia, there is an urgent need to improve both the speed and accuracy of diagnoses. More...

Current diagnostic methods such as brain scans and lumbar punctures are not only time-consuming and uncomfortable but are also not consistently available across dementia services in the UK. A biomarker is a measurable indicator of a person’s health that can be assessed through blood tests. Blood-based biomarkers could provide a cost-effective, accurate, and non-invasive tool to transform dementia diagnosis. These biomarkers are set to play a crucial role in speeding up the dementia diagnosis process. Researchers are developing tests to detect two proteins—amyloid and tau—that accumulate in the brain in Alzheimer’s disease. When found in blood, these proteins could indicate their presence in the brain as well. As amyloid and tau build up in the brain, the body attempts to clear them, which can result in their presence in spinal fluid, the protective liquid surrounding the brain and spinal cord. This fluid is connected to the bloodstream through the brain-blood barrier.

While Alzheimer’s disease blood tests have already been extensively researched, showing they can accurately diagnose the disease and distinguish it from other types of dementia, they have not yet been tested in diverse UK patient groups. This lack of evidence prevents their integration into the NHS, and more research is needed to confirm their clinical applicability in the UK. Now, Alzheimer’s Society (Plymouth, UK) is working toward introducing dementia blood tests to the NHS within five years through the Blood Biomarker Challenge, a GBP 5 million initiative aimed at revolutionizing dementia diagnosis in the UK. The collaborative project will test existing and new dementia blood tests across various dementia types, with one team focusing on p-tau217, a promising biomarker for Alzheimer’s disease. Both teams will evaluate how well these blood tests can detect the disease at different stages.

With new treatments like lecanemab and donanemab on the horizon for people with early Alzheimer’s disease, it is essential to prepare the NHS to ensure these drugs are available to all eligible patients. Early diagnosis is key to this, enabling patients to access support, participate in clinical trials, and benefit from new treatments as they become available. For blood tests to be used in clinical practice, they must meet the same high standards of sensitivity and specificity as current spinal fluid tests. The Blood Biomarker Challenge aims to gather the necessary evidence to demonstrate that blood tests for dementia-related diseases are accurate for patients with suspected dementia in the UK.

“New drugs targeting early-stage Alzheimer’s disease are just around the corner,” said Fiona Carragher, Director of Research and Influencing, Alzheimer’s Society. "But without a diagnosis, people simply won’t be able to access them if they are approved. This could absolutely revolutionize the way dementia is diagnosed."

Related Links:
Alzheimer's Society


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Biochemical Analyzer
iBC 900
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.